dc.contributor.author |
Ferguson, LR |
en |
dc.contributor.author |
Laing, Bobbi |
en |
dc.contributor.author |
Ferguson, Lynnette |
en |
dc.contributor.author |
Bishop, Karen |
en |
dc.date.accessioned |
2017-05-01T22:28:57Z |
en |
dc.date.issued |
2016-01 |
en |
dc.identifier.citation |
Molecular Nutrition and Food Research 60(1):119-133 Jan 2016 |
en |
dc.identifier.issn |
1613-4125 |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/32729 |
en |
dc.description.abstract |
With the endogenous formation of vitamin D being significantly curtailed because of public awareness of skin cancer dangers, attention is turning to dietary sources. Cumulative evidence has implicated vitamin D deficiency in increasing susceptibility to various gastrointestinal disorders, including colorectal cancer, inflammatory bowel diseases, diverticulitis, and irritable bowel syndrome. There is also reason to suggest adjunct vitamin D therapy for such diseases. Although there is justification for increasing vitamin D intake overall, optimal intakes will vary among individuals. Genomic technologies have revealed several hundreds of genes associated with vitamin D actions. The nature of these genes emphasizes the potentially negative implications of modulating vitamin D intakes in the absence of complementary human genetic and genomic data, including information on the gut microbiome. However, we are not yet in a position to apply this information. Genomic data (transcriptomics, metabolomics, proteomics, and metagenomics) could provide evidence that vitamin D sufficiency has been achieved. We suggest that there is an increasingly strong case for considering the more widespread use of vitamin D fortified foods and/or dietary supplements to benefit gastrointestinal health. However, intake levels might beneficially be informed by personalized genetic and genomic information, for optimal disease prevention and maintenance of remission. |
en |
dc.format.medium |
Print-Electronic |
en |
dc.language |
eng |
en |
dc.publisher |
John Wiley & Sons Ltd. |
en |
dc.relation.ispartofseries |
Molecular Nutrition and Food Research |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.subject |
Gastrointestinal Tract |
en |
dc.subject |
Humans |
en |
dc.subject |
Gastrointestinal Diseases |
en |
dc.subject |
Vitamin D Deficiency |
en |
dc.subject |
Vitamin D |
en |
dc.subject |
Diet |
en |
dc.subject |
Nutrition Assessment |
en |
dc.subject |
Risk Factors |
en |
dc.subject |
Genomics |
en |
dc.subject |
Nutritional Requirements |
en |
dc.subject |
Dietary Supplements |
en |
dc.subject |
Food, Fortified |
en |
dc.subject |
Cost-Benefit Analysis |
en |
dc.subject |
Randomized Controlled Trials as Topic |
en |
dc.subject |
Gastrointestinal Microbiome |
en |
dc.title |
The role of vitamin D in reducing gastrointestinal disease risk and assessment of individual dietary intake needs: Focus on genetic and genomic technologies |
en |
dc.type |
Journal Article |
en |
dc.identifier.doi |
10.1002/mnfr.201500243 |
en |
pubs.issue |
1 |
en |
pubs.begin-page |
119 |
en |
pubs.volume |
60 |
en |
dc.rights.holder |
Copyright: John Wiley & Sons Ltd. |
en |
dc.identifier.pmid |
26251177 |
en |
pubs.end-page |
133 |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Article |
en |
pubs.elements-id |
516926 |
en |
pubs.org-id |
Medical and Health Sciences |
en |
pubs.org-id |
Medical Sciences |
en |
pubs.org-id |
Auckland Cancer Research |
en |
pubs.org-id |
Nursing |
en |
dc.identifier.eissn |
1613-4133 |
en |
pubs.record-created-at-source-date |
2017-05-02 |
en |
pubs.dimensions-id |
26251177 |
en |